Alzheimer’s disease is the most prevalent form of dementia. Although it was discovered about a century ago, the first drugs applied in treatment were only introduced in therapy in the last 30 years. This book focuses on the clinical pharmacology of drugs that aim to delay the progression of Alzheimer’s disease, such as anticholinesterases and glutamate receptor antagonists, as well as treatment for the behavioral changes caused by the progression of the disease: antidepressants, antipsychotics, anxiolytics, and mood stabilizers. In addition, it describes important information about the pathophysiology and diagnostic methods of Alzheimer’s disease, emergency situations conditioned by the dementia process, and presents new perspectives for the treatment of Alzheimer’s disease. The ten chapters cover topics such as mechanism of action, dosage regimen, adverse reactions, drug interactions, toxicity profiles, among other information of clinical relevance. The work comprises evidence-based studies, providing a valuable resource for analyzing, prescribing and monitoring patients being treated for Alzheimer’s disease. Written by experts with solid professional experience, this book will appeal to pharmacologists, geriatricians, neurologists, psychiatrists, biomedical clinicians, and other healthcare professionals.